Clinical trial study of the therapeutic effect of Ivermectin, besides Kaletra and Chloroquinein in patients with Coronavirus disease 2019 (COVID-19)

A randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200422047168N2

Enrollment

Registered

2020-05-30

Start date

2020-05-30

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. Covid-19, confirmed cases, positive test result

Interventions

Intervention 1: Intervention group: On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: People over 18 years old Real-time PCR test results for SARS-CoV-2 virus were positive after sampling (nasopharynx and oropharynx swab samples) The manifestations of virus pneumonia in CT scans of their lungs were quite obvious. Their O2 Saturation percentage were 93% or lower

Exclusion criteria

Exclusion criteria: History of renal failure Taking drugs that interfere with Ivermectin Patients who have been admitted to other clinical trials

Design outcomes

Primary

Measure	Time frame
Reduce the mortality rate of patients with Covid-19. Timepoint: days 0-7. Method of measurement: Based on the percentage of discharged Covid-19 patients.	—

Secondary

Measure	Time frame
Treatment period. Timepoint: 0-7. Method of measurement: Based on the days numbers of the drug usage.;Duration of infection. Timepoint: 0-7. Method of measurement: Based on the patient's clinical symptoms.;Duration of admission time. Timepoint: 0-7. Method of measurement: Number of admission days due to Covid-19.;Duration of ICU admission time. Timepoint: 0-7. Method of measurement: Number of ICU admission days due to Covid-19.;Fever. Timepoint: 0-7. Method of measurement: Rising body temperature.;Blood oxygen saturation percentage. Timepoint: 0-7. Method of measurement: O2 saturation percentage.;Respiratory rate. Timepoint: 0-7. Method of measurement: respiratory rate per minute.;Heart rate. Timepoint: 0-7. Method of measurement: heart rate per minute.;Discharge situation. Timepoint: 0-7. Method of measurement: Alive or dead.;Use non-invasive respiratory methods. Timepoint: 0-7. Method of measurement: Patients percentage that be supported by non-invasive breathing methods.;Use invasive respiratory methods. Timepoint: 0-7. Method of measurement: Patients percentage that be supported by invasive breathing methods.	—

Measure

Time frame

Treatment period. Timepoint: 0-7. Method of measurement: Based on the days numbers of the drug usage.;Duration of infection. Timepoint: 0-7. Method of measurement: Based on the patient's clinical symptoms.;Duration of admission time. Timepoint: 0-7. Method of measurement: Number of admission days due to Covid-19.;Duration of ICU admission time. Timepoint: 0-7. Method of measurement: Number of ICU admission days due to Covid-19.;Fever. Timepoint: 0-7. Method of measurement: Rising body temperature.;Blood oxygen saturation percentage. Timepoint: 0-7. Method of measurement: O2 saturation percentage.;Respiratory rate. Timepoint: 0-7. Method of measurement: respiratory rate per minute.;Heart rate. Timepoint: 0-7. Method of measurement: heart rate per minute.;Discharge situation. Timepoint: 0-7. Method of measurement: Alive or dead.;Use non-invasive respiratory methods. Timepoint: 0-7. Method of measurement: Patients percentage that be supported by non-invasive breathing methods.;Use invasive respiratory methods. Timepoint: 0-7. Method of measurement: Patients percentage that be supported by invasive breathing methods.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhvaz University of Medical Sciences

Ahvaz University of Medical Sciences

zahrashokati@gmail.com+98 61 3333 5678

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026